10-Q · May 8, 2026
Gyre Therapeutics reported Q1 2026 revenues of $22.5 million, slightly up from $22.1 million in the prior year but below expectations. The company recorded a net loss of $9.9 million, a stark contrast to the $3.7…
Earnings analysis · 10-Q
GYRE earnings analysis
Filed August 7, 2026 · Our reading of the company's report
The latest report
Gyre’s Q2 2026 revenue of $29.105 million improved 26.5% sequentially and 7.8% year over year, and exceeded consensus by 10.1%, but the $0.12 EPS loss was twice the expected $0.06 loss and worsened from the $0.10 loss…
Read full summary
Gyre’s Q2 2026 revenue of $29.105 million improved 26.5% sequentially and 7.8% year over year, and exceeded consensus by 10.1%, but the $0.12 EPS loss was twice the expected $0.06 loss and worsened from the $0.10 loss in Q1. The supplied filing excerpt does not provide current gross margin, operating margin, free cash flow, segment results, or updated quantitative guidance. The most material newly disclosed risk is concentrated ownership and potential forced selling of shares pledged against GNI Japan’s JPY 20 billion loan.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.12
What stood out
-
Revenue Rebounded Sequentially
Revenue was $29.105 million, up from $23 million in Q1 2026, a 26.5% sequential increase, and up from $27 million in Q2 2025, a 7.8% year-over-year increase. Revenue also exceeded the $26.44 million consensus estimate by 10.1%.
-
Revenue Beat, EPS Missed
Reported EPS was a loss of $0.12 versus a $0.06 consensus loss, representing a $0.06 miss and a 100% larger loss than estimated.
-
Earnings Loss Worsened
Reported EPS declined from a $0.10 loss in Q1 2026 to a $0.12 loss in Q2 2026, indicating sequential earnings deterioration despite the revenue recovery.
-
Disclosure Controls Effective
Management concluded that disclosure controls and procedures were effective as of June 30, 2026, providing reasonable assurance over required reporting.
What to watch
-
Concentrated Ownership and Thin Float
The company added a new risk that its common stock is thinly traded and ownership is concentrated. GNI Japan and its subsidiaries beneficially own a majority of outstanding shares, while the public trading float is limited, increasing the risk that substantial sales could cause a significant price decline.
-
Pledged Shares Create Selling Risk
GNI Japan disclosed a JPY 20 billion term loan secured by shares of Gyre held by the GNI Parties. The loan was funded on July 1, 2026, matures on July 1, 2027, and a default could lead to foreclosure and sale of pledged shares, potentially causing a change in control.
-
Merger Integration Controls
The company is evaluating the impact of the Merger on internal control over financial reporting. The transaction closed on May 4, 2026, and management stated that this evaluation could materially affect internal controls.
-
Board Composition Changed
The Board of Directors was reduced from 10 members to 9 following the July 18, 2026 death of director David M. Epstein, Ph.D., creating a governance and oversight change after the quarter end.
Management's outlook
The provided 10-Q excerpt does not include a quantitative outlook. Prior annual revenue guidance was $100.5 million to $111 million, but current-period guidance status is not stated in the supplied filing text.
Earlier filings 4
10-K · March 13, 2026
Gyre Therapeutics is a commercial-stage biopharma focused on antifibrotic small molecules with a China commercial franchise anchored by ETUARY® (pirfenidone) and an advancing liver-fibrosis pipeline led by Hydronidone.…
10-Q · November 7, 2025
Gyre reported Q3 revenue of $30,564 (thousands) and diluted EPS of $0.03, with operating income of $6,925 (thousands) driving a 22.7% operating margin. Cash and cash equivalents increased to $40,402 (thousands)…
10-Q · August 11, 2025
Gyre reported Q2 revenue of $26.8M, up $1.55M (6.1%) year-over-year and up $4.71M (21.4%) sequentially, while diluted EPS was $0.00. Gross margin remained high at 95.7% but operating margin compressed to 8.1% from…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.